© The Author 2006. Published by Oxford University Press.
ARTICLE |
Menopausal Hormone Therapy and Ovarian Cancer Risk in the National Institutes of Health–AARP Diet and Health Study Cohort
Affiliations of authors: Hormonal and Reproductive Epidemiology Branch (JVL, LAB), Nutritional Epidemiology Branch (MFL, TM, AS), and Epidemiology and Biostatistics Program (PH), Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD; AARP, Washington DC (AH)
Correspondence to: James V. Lacey Jr., PhD, 6120 Executive Blvd., Room 5030, Rockville, MD 20852-7234 (e-mail: jimlacey{at}nih.gov).
Background: Recent studies offer conflicting data on risks of ovarian cancer in users of menopausal hormone therapy. Some findings of increased risks associated with unopposed estrogen use are based on older studies of women with intact uteri, and small sample size and incomplete exposure information have limited the data on estrogen plus progestin associations. Methods: The National Institutes of Health–AARP Diet and Health Study Cohort included 97 638 women aged 50–71 years at baseline who completed two questionnaires (1995–1996 and 1996–1997). We identified 214 incident ovarian cancers among these women through the year 2000 using data from state cancer registries and mortality indexes. We estimated relative risks (RRs) of ovarian cancer for detailed hormone therapy exposures using multivariable proportional hazards regression models. All statistical tests were two-sided. Results: Use of unopposed estrogen for fewer than 10 years was not associated with ovarian cancer. Compared with use of no hormone therapy, use of unopposed estrogen for 10 or more years was statistically significantly associated with ovarian cancer among all women (RR = 1.89, 95% confidence interval [CI] = 1.22 to 2.95; P = .004; 56 versus 72 ovarian cancers per 100 000 person-years, respectively) and, albeit not statistically significantly, among women with hysterectomy (n = 19 359, RR = 1.70, 95% CI = 0.87 to 3.31; P = .06). Among the 73 483 women with intact uteri, 51 698 had used no hormone therapy or only estrogen plus progestin. Compared with no hormone therapy use, 5 or more years of use of sequential (progestin for <15 days per cycle; RR = 3.09, 95% CI = 1.68 to 5.68; P<.001; 49 versus 108 per 100 000 person-years) or continuous (progestin for 
15 days per cycle; RR = 1.82, 95% CI = 1.03 to 3.23; P = .02; 49 versus 66 per 100 000 person-years) estrogen plus progestin regimens were statistically significantly associated with ovarian cancer. Conclusions: Long durations of use of unopposed estrogen and of estrogen plus progestin, especially sequential regimens, are associated with increased ovarian cancer risk. These data expand the range of possible risks associated with menopausal hormone therapy.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. V. Lacey Jr. Ovarian Cancer and Menopausal Hormone Therapy: More Data and New Questions Cancer Epidemiol. Biomarkers Prev., December 1, 2007; 16(12): 2524 - 2525. [Full Text] [PDF]
|
|
|
|
|
|
M. A. Rossing, K. L. Cushing-Haugen, K. G. Wicklund, J. A. Doherty, and N. S. Weiss Menopausal Hormone Therapy and Risk of Epithelial Ovarian Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2007; 16(12): 2548 - 2556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Beesley, S. J. Jordan, A. B. Spurdle, H. Song, S. J. Ramus, S. K. Kjaer, E. Hogdall, R. A. DiCioccio, V. McGuire, A. S. Whittemore, et al. Association Between Single-Nucleotide Polymorphisms in Hormone Metabolism and DNA Repair Genes and Epithelial Ovarian Cancer: Results from Two Australian Studies and an Additional Validation Set Cancer Epidemiol. Biomarkers Prev., December 1, 2007; 16(12): 2557 - 2565. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Baik, M. Lambe, Q. Liu, S. Cnattingius, L. A. Mucci, T. Riman, A. Ekbom, H.-O. Adami, and C.-C. Hsieh Gender of Offspring and Maternal Risk of Invasive Epithelial Ovarian Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2314 - 2320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Greiser, E. M. Greiser, and M. Doren Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis Hum. Reprod. Update, September 1, 2007; 13(5): 453 - 463. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Does Menopausal Hormone Therapy Increase Risk for Ovarian Cancer? Journal Watch (General), November 2, 2006; 2006(1102): 3 - 3. [Full Text]
|
|